ClinicalTrials.gg
Not yet recruitingNCT06335355Updated Mar 28, 2024

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

A Phase 2/3 interventional study of Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin and Camrelizumab + Pemetrexed + Carboplatin in Non-squamous Non-small Cell Lung Cancer, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-28.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 16 under way, 3 of them phase 3. adebrelimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
4th of 16
401 · median 85
Started
2024
with 3 others
Phase 2/3
Only one
of the 16
Primary completion
2028-10
later than 9 of 15 live
Registered
5th of 16
by date
Lead sponsor
1 of 16
Shanghai Shengdi Pharmaceutical Co., Ltd

Among the 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by planned enrollment, is one of 4 that started in 2024, is the only one in phase 2/3, reaches primary completion later than 9 of the 15 other live ones, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

About adebrelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing adebrelimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Evaluating the Efficacy and safety of Adebrelimab in Combination with Platinum-based Doublet Chemotherapy and SHR-8068 as First-line Therapy for Patients with Advanced or Metastatic NSCLC Carrying STK11/KEAP1/KRAS Mutations

03

Conditions studied

  • Non-squamous Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant voluntarily joins this clinical research study, understands the research procedures, and is capable of providing written by signing the Informed Consent Form.
  2. At the time of signing the Informed Consent Form, participants must be between the ages of 18 and 75 years old (inclusive), with no gender restrictions.
  3. Diagnosed with advanced or non-squamous NSCLC (non-small cell lung cancer) confirmed by histology or cytology.
  4. At least one measurable tumor lesion outside the central nervous system that meets the v1.1guidelines .
  5. The participant is expected to have a of at least 12 weeks.
  6. Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are also allowed.
  7. The participant must have adequate bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. or cytologically confirmed mixed Small Cell Lung Cancer (SCLC), sarcomatoid carcinoma, or neuroendocrine carcinoma.
  2. Subjects with untreated or active Central Nervous System (CNS) , those with a history of , or those currently presenting with leptomeningeal metastasis.
  3. Subjects with spinal cord compression that has not been radically treated by surgery and/or radiotherapy.
  4. Subjects with inadequately controlled pain related to their tumor(s).
  5. Subjects with a history of or concurrent other , except for basal cell carcinoma of the skin, superficial bladder cancer, cutaneous squamous cell carcinoma, in situ cervical cancer, localized prostate cancer, ductal carcinoma in situ following mastectomy (allowing for hormonal treatment for non-metastatic prostate or breast cancer), and papillary thyroid cancer which have achieved complete remission for at least 5 years prior to screening and do not require or are not expected to require further treatment during the study period.
  6. Subjects who have received Chinese herbal anti-tumor treatment within 2 weeks prior to initiating the study treatment.
  7. Subjects whose toxicities and/or complications from previous interventions have not resolved to National Cancer Institute (NCI-CTCAE 5.0) Grade ≤1.
  8. Subjects participating in another clinical study or whose initiation of study treatment is less than 4 weeks since the end of the last clinical study (last dose administration), or less than five half-lives of that study drug, whichever is shorter.
  9. Subjects who have received systemic immunostimulant treatment within 4 weeks prior to starting the study treatment.
  10. Subjects who have received systemic treatment within 2 weeks prior to starting the study treatment.
  11. Subjects with any active, known, or suspected disease.
  12. Subjects with severe heart disease.
  13. Subjects who have experienced arterial or venous thrombotic events within 3 months prior to starting the study treatment.
  14. Subjects with active syphilis infection.
  15. Subjects who have had a severe infection within 4 weeks prior to starting the study treatment.
  16. Subjects who have previously undergone or are planning to undergo hematopoietic stem cell transplantation or organ transplantation.
  17. Subjects with a history of severe reactions to other monoclonal antibodies.
  18. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study period.
  19. Subjects with a history of substance abuse of psychoactive drugs, alcoholism, or drug addiction.
  20. Subjects whom the investigator believes have any medical condition (such as pulmonary, metabolic, endocrine, or neurological diseases, congenital disorders, etc.), psychiatric conditions, or social circumstances that could potentially interfere with the subject's rights, safety, health, or ability to provide , cooperate, and participate in the study, or interfere with the assessment of the drug, interpretation of subject safety data, or study results.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
401 participants (estimated)

Study arms

  • Experimental
    Treatment group A

    Drug: Adebrelimab + SHR-8068 + Pemetrexed + Carboplatin

  • Active comparator
    Treatment group B

    Drug: Camrelizumab + Pemetrexed + Carboplatin

  • Active comparator
    Treatment group C

    Drug: Adebrelimab + Pemetrexed + Carboplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Investigator-assessed Objective Response Rate (Phase One)

    Time frame: about 3 years

  2. Overall Survival (Phase Two)

    Time frame: about 3.5 years

Secondary outcomes

  1. The incidence and severity of Adverse Events (AEs) (Phases One and Two)

    Time frame: about 4.5 years

  2. Duration of Response (DoR) based on Investigator Assessment (Phases One and Two)

    Time frame: about 6.5 years

  3. Disease Control Rate (DCR) based on Investigator Assessment (Phases One and Two)

    Time frame: about 6.5 years

  4. Progression-Free Survival (PFS) based on Investigator Assessment (Phases One and Two)

    Time frame: about 6.5 years

  5. Overall Survival (OS) (Phase One)

    Time frame: about 3.5 years

  6. Objective Response Rate (ORR) based on Investigator Assessment (Phase Two)

    Time frame: about 4.5 years

07

Study locations

1 site
  • Affiliated Tumor Hospital of Shandong First Medical University
    Jinan, Shandong 250117, China
    • Jinming Yu · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Oct 2028, 55 months later.

Of 56 phase 2/3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40. This study's planned 55 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Mar 28, 2024
StartEst.
Mar 2024
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2030
Last update
Mar 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06335355
Responsible party
Sponsor
First posted
Mar 28, 2024
Start date
Mar 2024 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2030 (estimated)
Last update
Mar 28, 2024

Study contacts

Junli Qang
Contact
Junli.wang@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adebrelimab · Anti-CTLA-4 Monoclonal Antibody SHR-8068 · Pemetrexed · Carboplatin

Start the discussion